Ocuphire Pharma
global partnership with for ophthalmic solution million fully funded development and commercialization for all indications million in regulatory and sales milestones first milestone payment of million on approval for pharmacologically induced mydriasis indication tiered double digit royalties through | Ocuphire Pharma
Company
Deck date
November 2023
Slide
33 of 42
Similar slides by Ocuphire Pharma
Investor Presentation
August 2023
Investor Presentation
May 2023
Related slides by other companies
Results
September 2022
Investor Presentation
March 2024
Investor Presentation
October 2024
Investor Presentation
November 2024
Other recent decks by Ocuphire Pharma
Investor Presentation
August 2023
Investor Presentation
May 2023
Results
January 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies